OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.

Acquired loss of hypothalamic orexin (hypocretin)-producing neurons causes the chronic sleep disorder narcolepsy-cataplexy. Orexin replacement therapy using orexin receptor agonists is expected as a mechanistic treatment for narcolepsy. Orexins act on two receptor subtypes, OX1R and OX2R, the latter...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Hikari Yamamoto, Yasuyuki Nagumo, Yukiko Ishikawa, Yoko Irukayama-Tomobe, Yukiko Namekawa, Tsuyoshi Nemoto, Hiromu Tanaka, Genki Takahashi, Akihisa Tokuda, Tsuyoshi Saitoh, Hiroshi Nagase, Hiromasa Funato, Masashi Yanagisawa
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0271901&type=printable